Biohaven Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting
Biohaven (NYSE: BHVN) announced its presentation of 13 abstracts at the 2025 American Academy of Neurology Annual Meeting in San Diego (April 5-9, 2025). The presentations include 3 oral and 10 poster presentations showcasing the company's neuroscience pipeline across multiple development programs.
The presentations focus on various therapeutic areas including Kv7 ion channel modulation, extracellular protein degradation, TRPM3 antagonism, TYK2/JAK1 inhibition, and glutamate modulation. Key highlights include data on BHV-8000 for Parkinson's Disease, BHV-2100 for pain and migraine, and BHV-1310 for IgG reduction.
The company's Chief Medical Officer, Dr. Irfan Qureshi, emphasized their commitment to developing first-in-class therapies for neurological disorders with inadequate or no treatment options, anticipating critical value-creating milestones throughout 2025.
Biohaven (NYSE: BHVN) ha annunciato la presentazione di 13 abstract al Meeting Annuale dell'American Academy of Neurology del 2025 a San Diego (dal 5 al 9 aprile 2025). Le presentazioni includono 3 presentazioni orali e 10 poster che mostrano il pipeline neuroscientifico dell'azienda attraverso diversi programmi di sviluppo.
Le presentazioni si concentrano su varie aree terapeutiche, tra cui modulazione dei canali ionici Kv7, degradazione delle proteine extracellulari, antagonismo del TRPM3, inibizione di TYK2/JAK1 e modulazione del glutammato. I punti salienti includono dati su BHV-8000 per il morbo di Parkinson, BHV-2100 per il dolore e l'emicrania, e BHV-1310 per la riduzione dell'IgG.
Il Chief Medical Officer dell'azienda, Dr. Irfan Qureshi, ha sottolineato il loro impegno nello sviluppo di terapie innovative per i disturbi neurologici con opzioni di trattamento inadeguate o assenti, prevedendo importanti traguardi che creeranno valore nel corso del 2025.
Biohaven (NYSE: BHVN) anunció la presentación de 13 resúmenes en la Reunión Anual de la Academia Americana de Neurología de 2025 en San Diego (del 5 al 9 de abril de 2025). Las presentaciones incluyen 3 presentaciones orales y 10 carteles que muestran la cartera de neurociencia de la empresa a través de múltiples programas de desarrollo.
Las presentaciones se centran en diversas áreas terapéuticas, incluyendo modulación de canales iónicos Kv7, degradación de proteínas extracelulares, antagonismo de TRPM3, inhibición de TYK2/JAK1 y modulación de glutamato. Los aspectos más destacados incluyen datos sobre BHV-8000 para la enfermedad de Parkinson, BHV-2100 para el dolor y la migraña, y BHV-1310 para la reducción de IgG.
El Director Médico de la empresa, Dr. Irfan Qureshi, enfatizó su compromiso con el desarrollo de terapias de primera clase para trastornos neurológicos con opciones de tratamiento inadecuadas o inexistentes, anticipando hitos críticos que generarán valor a lo largo de 2025.
Biohaven (NYSE: BHVN)은 2025년 4월 5일부터 9일까지 샌디에이고에서 열리는 2025년 미국 신경학회 연례 회의에서 13개의 초록을 발표한다고 발표했습니다. 발표에는 회사의 신경과학 파이프라인을 여러 개발 프로그램을 통해 보여주는 3개의 구두 발표와 10개의 포스터 발표가 포함됩니다.
발표는 Kv7 이온 채널 조절, 세포외 단백질 분해, TRPM3 길항제, TYK2/JAK1 억제 및 글루타메이트 조절 등 다양한 치료 영역에 초점을 맞추고 있습니다. 주요 하이라이트로는 파킨슨병을 위한 BHV-8000, 통증 및 편두통을 위한 BHV-2100, IgG 감소를 위한 BHV-1310에 대한 데이터가 포함됩니다.
회사의 최고 의료 책임자인 Dr. Irfan Qureshi는 치료 옵션이 부족하거나 없는 신경학적 장애를 위한 1차 치료제를 개발하겠다는 의지를 강조하며, 2025년 동안 가치 창출의 중요한 이정표를 예상하고 있습니다.
Biohaven (NYSE: BHVN) a annoncé la présentation de 13 résumés lors de la Réunion Annuelle de l'American Academy of Neurology en 2025 à San Diego (du 5 au 9 avril 2025). Les présentations comprennent 3 présentations orales et 10 affiches mettant en avant le pipeline en neurosciences de l'entreprise à travers plusieurs programmes de développement.
Les présentations se concentrent sur diverses zones thérapeutiques, y compris la modulation des canaux ioniques Kv7, la dégradation des protéines extracellulaires, l'antagonisme du TRPM3, l'inhibition de TYK2/JAK1 et la modulation du glutamate. Les points forts incluent des données sur BHV-8000 pour la maladie de Parkinson, BHV-2100 pour la douleur et la migraine, et BHV-1310 pour la réduction de l'IgG.
Le directeur médical de l'entreprise, Dr. Irfan Qureshi, a souligné leur engagement à développer des thérapies de première classe pour les troubles neurologiques avec des options de traitement inadéquates ou inexistantes, anticipant des jalons créateurs de valeur tout au long de 2025.
Biohaven (NYSE: BHVN) gab bekannt, dass es 13 Abstracts auf der Jahrestagung der American Academy of Neurology 2025 in San Diego (5. bis 9. April 2025) präsentieren wird. Die Präsentationen umfassen 3 mündliche und 10 Posterpräsentationen, die die Neurowissenschafts-Pipeline des Unternehmens über mehrere Entwicklungsprogramme hinweg zeigen.
Die Präsentationen konzentrieren sich auf verschiedene therapeutische Bereiche, einschließlich Kv7-Ionenkanalmodulation, extrazelluläre Proteindegradation, TRPM3-Antagonismus, TYK2/JAK1-Hemmung und Glutamatmodulation. Zu den Höhepunkten gehören Daten zu BHV-8000 für die Parkinson-Krankheit, BHV-2100 für Schmerzen und Migräne sowie BHV-1310 zur IgG-Reduktion.
Der Chief Medical Officer des Unternehmens, Dr. Irfan Qureshi, betonte das Engagement für die Entwicklung von First-in-Class-Therapien für neurologische Erkrankungen mit unzureichenden oder keinen Behandlungsoptionen und erwartet im Jahr 2025 wichtige wertschöpfende Meilensteine.
- Diverse neuroscience pipeline with multiple drug candidates in development
- Strong presence at major scientific conference with 13 presentations
- Development of potential first-in-class therapies for unmet medical needs
- Multiple value-creating milestones expected throughout 2025
- All presented drug candidates still in early to mid-stage development
- No immediate revenue-generating products highlighted in the presentations
Irfan Qureshi, M.D., Chief Medical Officer of Biohaven, commented, "We are excited to highlight our clinical and scientific progress at the AAN Annual Meeting, including 3 oral presentations and 10 poster presentations, emphasizing Biohaven's innovation, leadership and commitment to developing potential first-in-class therapies for debilitating neurological disorders with inadequate or no treatment options. The team at Biohaven has been working urgently to advance our next-generation medicines as we aim to transform the way these diseases are treated. We look forward to achieving critical value-creating milestones throughout 2025 as we advance these assets across multiple high unmet need indications."
The complete list of Biohaven's accepted abstracts is below. Full abstracts can be viewed online at https://index.mirasmart.com/AAN2025/.
Oral Presentations:
BHV-8000, a Selective Brain-penetrant TYK2/JAK1 Inhibitor in Development for Neuroinflammatory and Neurodegenerative Diseases, Demonstrates Efficacy in an Alpha-Synuclein Overexpressing Parkinson's Disease Mouse Model
S4: Movement Disorders: Basic Science
Sunday 4/6/25 1:00-3:00pm (2:00-2:12pm)
Safety, Tolerability, and Pharmacokinetics of BHV-2100, a First-in-class TRPM3 Antagonist for Pain and Migraine
S11: Pain
Monday 4/7/25 11:15am-12:15pm (11:51am-12:03pm)
Novel Bispecific Degrader BHV-1310 Achieves Rapid, Robust, and Selective IgG Reduction in Preclinical Models including Nonhuman Primates
S18.009
Monday 4/7/25 1:00-3:00pm (2:36-2:48pm)
Poster Presentations:
A Qualitative Assessment of the Epilepsy Patient Experience Through Social Media and Web-Based Forums
P2: Epilepsy/Clinical Neurophysiology (EEG): Clinical Outcomes in Epilepsy
Sunday 4/6/25 8:00-9:00am
Novel Bispecific Degrader BHV-1310 Eliminates Intravascular and Interstitial IgG within Multiple Organs and Anatomical Structures Including the Neuromuscular Junction
P4: Autoimmune Neurology: Peripheral Autoimmune Neurology
Sunday 4/6/25 5:00-6:00pm
Comparative Effectiveness of Troriluzole Versus Untreated Natural History Cohorts in Spinocerebellar Ataxia Leveraging Propensity Score Matching Methods
P6: Movement Disorders: Ataxia 1
Monday 4/7/25 11:45-12:45
BHV-2100, a First-in-Class TRPM3 Antagonist in Development for the Treatment of Migraine
P7: Headache: Advances in Headache Treatment 1
Monday 4/7/25 5:00-6:00pm
Re-weighting MDS-UPDRS Parts II and III Items to Improve Assessment of Motor Decline in Untreated Parkinson's Disease
P7: Movement Disorders: Parkinson's Disease Management
Monday 4/7/25 5:00-6:00pm
Re-weighting MDS-UPDRS Part II and PDQ-39 Items to Detect Maximal Decline in Activities of Daily Living in Untreated Parkinson's disease
P7: Movement Disorders: Parkinson's Disease Management
Monday 4/7/25 5:00-6:00pm
A Modern Design for a Phase 2/3 Randomized, Double-blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BHV-7000 in Idiopathic Generalized Epilepsy with Generalized Tonic-Clonic Seizures
P8: Epilepsy/Clinical Neurophysiology (EEG): Anti-seizure Medications: Clinical Trials
Tuesday 4/8/25 8:00-9:00am
BHV-8000, a Selective Brain-Penetrant TYK2/JAK1 Inhibitor in Development for Neuroinflammatory and Neurodegenerative Diseases, Demonstrates Favorable PK/PD and Safety Profile in Phase 1 Studies
P9: General Neurology: New, Potential, and Innovative Treatments 1
Tuesday 4/8/25 11:45am-12:45pm
Phase 1 Multiple Ascending Dose Studies Demonstrate Favorable Safety and Tolerability of BHV-7000, a Novel Kv7 Potassium Channel Activator
P9: Epilepsy/Clinical Neurophysiology (EEG): Anti-seizure Medications: Mechanisms and Pharmacology
Tuesday 4/8/25 11:45am-12:45pm
Incorporating Patient Perspectives into a Composite Score for Measuring Disease Progression in Spinocerebellar Ataxia (SCA)
P12: Movement Disorders: Ataxia 2
Wednesday 4/9/25 11:45-12:45
Posters and presentations will be available on the Posters and Presentations page after the conference at www.biohaven.com.
About Biohaven
Biohaven is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. The company is advancing its innovative portfolio of therapeutics, leveraging its proven drug development experience and multiple proprietary drug development platforms. Biohaven's extensive clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for OCD and SCA; myostatin inhibition for neuromuscular and metabolic diseases, including SMA and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer.
Forward-looking Statements
This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including "continue", "plan", "will", "believe", "may", "expect", "anticipate", "potential first-in-class", "disrupt", "potentially revolutionize", "groundbreaking" and similar expressions, is intended to identify forward-looking statements. Investors are cautioned that any forward-looking statements, including statements regarding the future development, timing and potential marketing approval and commercialization of development candidates, are not guarantees of future performance or results and involve substantial risks and uncertainties. Actual results, developments and events may differ materially from those in the forward-looking statements as a result of various factors including: the expected timing, commencement and outcomes of Biohaven's planned and ongoing clinical trials; the timing of planned interactions and filings with the FDA; the timing and outcome of expected regulatory filings; complying with applicable US regulatory requirements; the potential commercialization of Biohaven's product candidates; and the effectiveness and safety of Biohaven's product candidates. Additional important factors to be considered in connection with forward-looking statements are described in Biohaven's filings with the Securities and Exchange Commission, including within the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations". The forward-looking statements are made as of the date of this news release, and Biohaven does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Investor Contact:
Jennifer Porcelli
Vice President, Investor Relations
jennifer.porcelli@biohavenpharma.com
+1 (201) 248-0741
Media Contact:
Mike Beyer
Sam Brown Inc.
mikebeyer@sambrown.com
+1 (312) 961-2502
View original content to download multimedia:https://www.prnewswire.com/news-releases/biohaven-presents-data-across-innovative-neuroscience-portfolio-at-the-2025-american-academy-of-neurology-aan-annual-meeting-302421403.html
SOURCE Biohaven Ltd.
FAQ
What are the key drug candidates presented by BHVN at AAN 2025?
How many presentations did BHVN make at the 2025 AAN meeting?
What therapeutic areas is BHVN focusing on according to the 2025 AAN presentations?
When and where was the 2025 AAN Annual Meeting held?
